Dai Fang, Duan Yu-Lian, Feng Qiang, Song Shu-Ling, Yang Ju-Lun, Lv Tao
College of Chemistry and Environmental Science, Qujing Normal University, Qujing, Yunnan, 655011, China.
Graduate School, Kunming Medical University, Kunming, Yunnan, China.
J Cancer. 2024 Mar 4;15(8):2373-2379. doi: 10.7150/jca.93733. eCollection 2024.
While CKLF-like MARVEL transmembrane domain containing 6 (CMTM6)'s role in stabilizing PD-L1 and immune evasion within tumors is established, its expression in lung cancer tissue and adjacent macrophages remains uncertain. The study aimed to elucidate this ambiguity by investigating CMTM6's role in non-small cell lung cancer (NSCLC) prognosis. Employing immunohistochemical staining on 141 NSCLC and 110 adjacent normal lung tissue samples, CMTM6 expression was evaluated using the HSCORE system. Interestingly, NSCLC exhibited significantly higher CMTM6 levels (161.04±86.60) compared to normal tissues (71.20±45.10) ( < 0.001), detected not only in cancer cells but also in macrophages, lymphocytes, and nearby bronchial epithelial cells. Stratifying patients by CMTM6 levels unveiled a correlation between heightened expression and poorer overall survival ( = 0.003), alongside a link to tumor-infiltrating lymphocytes (TIL) ( = 0.037), especially in cases with increased TIL. Multivariate analysis identified CMTM6 as an independent predictor of overall survival ( = 0.009), implying that elevated CMTM6 expression in NSCLC might signify an adverse prognostic marker for patient outcomes.
虽然含CKLF样MARVEL跨膜结构域6（CMTM6）在稳定肿瘤内程序性死亡受体配体1（PD-L1）及免疫逃逸中的作用已明确，但它在肺癌组织及邻近巨噬细胞中的表达仍不确定。本研究旨在通过调查CMTM6在非小细胞肺癌（NSCLC）预后中的作用来阐明这一不确定性。对141例NSCLC和110例邻近正常肺组织样本进行免疫组织化学染色，使用HSCORE系统评估CMTM6表达。有趣的是，与正常组织（71.20±45.10）相比，NSCLC中CMTM6水平显著更高（161.04±86.60）（<0.001），不仅在癌细胞中，而且在巨噬细胞、淋巴细胞及附近支气管上皮细胞中均检测到。按CMTM6水平对患者进行分层显示，表达升高与总体生存率较差相关（=0.003），同时与肿瘤浸润淋巴细胞（TIL）有关（=0.037），尤其是在TIL增加的病例中。多变量分析确定CMTM6为总体生存的独立预测因子（=0.009），这意味着NSCLC中CMTM6表达升高可能预示患者预后不良。
